Total submissions: 32
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000162461 | SCV000212818 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-11-17 | criteria provided, single submitter | clinical testing | The p.T125M variant (also known as c.374C>T), located in coding exon 3 of the TP53 gene, results from a C to T substitution at nucleotide position 374. The threonine at codon 125 is replaced by methionine, an amino acid with similar properties. This variant is in the DNA binding domain of the TP53 protein and is reported to have non-functional transactivation in yeast based assays (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9). However, studies conducted in human cell lines indicate this alteration is proficient at growth suppression and has no dominant negative effect (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This variant has been reported in multiple individuals with early-onset breast cancer (Maxwell KN et al. Genet. Med. 2015 Aug;17:630-8; Shirts BH et al. Genet. Med. 2016 10;18:974-81; Weitzel JN et al. Cancer. 2019 Aug;125:2829-2836) as well as in two individuals with childhood-onset adrenocortical carcinoma (Bougeard G et al. J. Clin. Oncol. 2015 Jul;33:2345-52). Another alteration at the same codon, p.T125R (c.374C>G), has been reported in several families meeting clinical criteria for Li Fraumeni syndrome (Morgan J et al Hum Mutat. 2010 Apr;31(4):484-91; Waszak SM et al. Lancet Oncol. 2018 06;19:785-798; Li JY et al. Int J Cancer. 2019 01;144:281-289). In addition, several functional studies indicate that p.T125R is deleterious (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul;100:8424-9; Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387; Menendez D et al. Mol. Cell. Biol. 2006 Mar;26:2297-308). The p.T125M amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
University of Washington Department of Laboratory Medicine, |
RCV000162461 | SCV000266132 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2015-11-20 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000237013 | SCV000292695 | uncertain significance | not provided | 2023-05-30 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies demonstrate significantly reduced transactivation in some studies but higher activity in others, and no loss of growth suppression activity (Kato et al., 2003, Perez et al., 2016, Giacomelli et al., 2018, Kotler et al., 2018, Pinto et al., 2021); Published functional studies investigating splicing found a low level of aberrant transcripts also present in wildtype controls, suggesting they may be naturally occurring isoforms (Pinto et al., 2021); Although this variant has been observed in individuals with a personal history of LFS-related cancers, such as adrenocortical carcinoma or early-onset breast cancer, it has not to our knowledge been reported in a family meeting classic LFS criteria or as a de novo variant. This variant has also been reported in unaffected adults and others whose histories are not consistent with LFS. (Bougeard et al., 2015, Maxwell et al., 2015, Shirts et al., 2016, de Andrade et al., 2017, Hu et al., 2018, Weber-Lasalle et al., 2018, Lu et al., 2019, Weitzel et al., 2019, Pinto et al., 2021).; This variant is associated with the following publications: (PMID: 27237367, 19046423, 21118481, 26849095, 26845104, 14559903, 20436704, 25503501, 10761705, 27998968, 27022024, 28369373, 26014290, 29319699, 12826609, 29079180, 30216591, 28861920, 30352134, 29922827, 30128536, 28472496, 30720243, 30840781, 31016814, 31206626, 31105275, 29979965, 30224644, 34675114, 15510160, 31794323, 35664418, 35426462) |
Invitae | RCV000457119 | SCV000545359 | pathogenic | Li-Fraumeni syndrome | 2024-01-30 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 125 of the TP53 protein (p.Thr125Met). This variant is present in population databases (rs786201057, gnomAD 0.01%). This missense change has been observed in individuals with adrenocortical carcinoma, breast cancer, and/or Li-Fraumeni-associated cancers (PMID: 25503501, 26014290, 26845104; Invitae). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 183748). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects TP53 function (PMID: 12826609). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (Invitae). This variant disrupts the p.Thr125 amino acid residue in TP53. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12826609, 16508005; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Counsyl | RCV000576336 | SCV000677813 | likely pathogenic | Li-Fraumeni syndrome 1 | 2016-10-18 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162461 | SCV000691590 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2023-08-23 | criteria provided, single submitter | clinical testing | This missense variant replaces threonine with methionine at codon 125 DNA binding domain of the TP53 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Splice site prediction tools are inconclusive regarding the impact of this variant on RNA splicing. One RNA study showed use of a cryptic donor splice site and exon 4 skipping (PMID: 34675114). Functional studies have shown the mutant protein to be defective in transactivation activity (PMID: 10761705, 12826609, 28369373) and functional in human cell growth assays (PMID: 29979965, 30224644). This variant has been reported in individuals meeting the Chompret criteria for Li-Fraumeni syndrome, including individuals affected with adrenocortical carcinoma (PMID: 26014290, 28369373; DOI:10.7759/cureus.24602) and individuals affected with early-onset breast cancer (PMID: 25503501, 34675114). This variant has been reported in additional individuals affected with breast cancer (PMID: 26845104, 31206626, 30128536, 34675114), ovarian cancer (PMID: 30216591), and bladder urothelial carcinoma (PMID: 34240179). This variant has been identified in 1/31400 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Different missense variants occurring at the same amino acid position, p.Thr125Arg and p.Thr125Lys, are known to be disease-causing (ClinVar variation ID: 376667, 216465), indicating that threonine at this position is important for TP53 function. Based on the available evidence, this variant is classified as Likely Pathogenic. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000237013 | SCV001134868 | likely pathogenic | not provided | 2019-02-12 | criteria provided, single submitter | clinical testing | The best available variant frequency is uninformative. Predicted to have a damaging effect on the protein. Located in potentially important domain of the protein. Two other pathogenic or likely pathogenic variants affect the same amino acid. Predicted to negatively affect a known splice site. Assessment of experimental evidence suggests this variant results in abnormal protein function. |
Sema4, |
RCV000162461 | SCV002530451 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-11-27 | criteria provided, single submitter | curation | |
Cancer Variant Interpretation Group UK, |
RCV000162461 | SCV002760194 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-05-14 | criteria provided, single submitter | curation | Data included in classification: aGVGD: Class C65 and BayesDel score 0.5 (PP3_mod) 16 entries on cancer hotspots (PM1_mod) Bougeard et al. 2015: ACC in 2 children, Rana et al, 2019: 4 breast cancer cases and 1 sarcoma case, 14 observations in Ambry lab, 6 of which meet Chompret criteria (PS4_str) Data not included in classification: Conflicting functional evidence: Giacomelli et al. Nat Genet. 2018: NO DNE AND NO LOF Kato et al. PNAS 2003: Transactivation Class: non-functional Zerdoumi et al. HMG 2017: Dominant negative effect: ~75% decrease in p53 functionality score of lymphocytes compared to wild-type. Other classifications: Invitae (2020): Pathogenic; Ambry (2020) Counsyl (2016), Color (2015): Likely pathogenic; GeneDx (2019): VUS |
Ce |
RCV000237013 | SCV003917884 | likely pathogenic | not provided | 2023-07-01 | criteria provided, single submitter | clinical testing | TP53: PM2, PM5, PS4:Moderate |
Baylor Genetics | RCV003462117 | SCV004206216 | pathogenic | Adrenocortical carcinoma, hereditary | 2023-10-19 | criteria provided, single submitter | clinical testing | |
Database of Curated Mutations |
RCV000430781 | SCV000509781 | likely pathogenic | Ovarian serous cystadenocarcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000441098 | SCV000509782 | likely pathogenic | Gastric adenocarcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000421688 | SCV000509783 | likely pathogenic | Squamous cell lung carcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000431915 | SCV000509784 | likely pathogenic | Pancreatic adenocarcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000438666 | SCV000509785 | likely pathogenic | Papillary renal cell carcinoma type 1 | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000421040 | SCV000509786 | likely pathogenic | Neoplasm of brain | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000433024 | SCV000509787 | likely pathogenic | Malignant melanoma of skin | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000443535 | SCV000509788 | likely pathogenic | Brainstem glioma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000425628 | SCV000509789 | likely pathogenic | Neoplasm of the large intestine | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000432405 | SCV000509790 | likely pathogenic | Lung adenocarcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000442735 | SCV000509791 | likely pathogenic | Carcinoma of esophagus | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000426825 | SCV000509792 | likely pathogenic | Small cell lung carcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000436631 | SCV000509793 | likely pathogenic | Squamous cell carcinoma of the skin | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000419372 | SCV000509794 | likely pathogenic | Squamous cell carcinoma of the head and neck | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000427448 | SCV000509795 | likely pathogenic | Breast neoplasm | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000438105 | SCV000509796 | likely pathogenic | Hepatocellular carcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000420028 | SCV000509797 | likely pathogenic | Acute myeloid leukemia | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000428519 | SCV000509798 | likely pathogenic | Adrenal cortex carcinoma | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000439150 | SCV000509799 | likely pathogenic | Transitional cell carcinoma of the bladder | 2016-05-31 | no assertion criteria provided | literature only | |
Database of Curated Mutations |
RCV000417610 | SCV000509800 | likely pathogenic | Glioblastoma | 2016-05-31 | no assertion criteria provided | literature only | |
BRCAlab, |
RCV000162461 | SCV002589020 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-08-26 | no assertion criteria provided | clinical testing |